---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-037592"
form_type: "8-K"
ticker: "PULM"
cik: "0001574235"
company_name: "Pulmatrix, Inc."
filed_at: "2026-08-13T12:15:11+00:00"
generated_at: "2026-08-13T12:20:19.949435+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pulmatrix Q2 net loss $1.0M; cash $2.2M; merger with Eos on track for Q3 close

## Summary
- Q2 net loss $1.036M ($0.29/share) vs $1.549M loss year ago; R&D expenses <$0.1M.
- Cash and equivalents $2.2M plus $0.7M restricted; going concern assumption within one year.
- Merger with Eos SENOLYTIX expected to close Q3 2026; Form S-4 filed July 9, amended Aug 3.
- G&A expenses down to $1.0M from $1.5M; all clinical development on hold to license/monetize assets.
- iSPERSE patent portfolio ~142 granted patents, 17 US; PUR1900 Phase 3 in India by Cipla.

## SEC filing metadata
- accession: 0001493152-26-037592
- form_type: 8-K
- ticker: PULM
- cik: 0001574235
- company_name: Pulmatrix, Inc.
- filed_at: 2026-08-13T12:15:11+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574235/000149315226037592/0001493152-26-037592-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574235/000149315226037592/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-037592
- JSON: https://secwatch.observer/filing/0001493152-26-037592.json
- Plain text: https://secwatch.observer/filing/0001493152-26-037592.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.